Prolific Machines logo

Prolific Machines

Emerging

Prolific Machines is a Berkeley-based biotech company using light to control cell growth and differentiation, dramatically reducing bioreactor costs for cultivated meat and cell therapy; raised $55M+ including a $36M Series B in 2023;

Best for: Light-Activated Cell Growth & Biomanufacturing TechnologyEmerging, rapid growth
Life Sciences & BioTechLight-Activated Cell Growth & Biomanufacturing TechnologyWebsiteUpdated May 2026

Company Overview

About Prolific Machines

Prolific Machines is a Berkeley, California-based biomanufacturing technology company founded in 2020 by Deniz Kent, Joshua Mich, and Declan Jones that has developed a pioneering approach to cell biology: using light — specifically engineered light-sensitive proteins (optogenetics) — to control the growth and differentiation of stem cells and other mammalian cells in bioreactors. Traditional cell culture requires expensive biological growth factors (proteins such as FGF2 and TGF-β) added to culture media to drive cell proliferation and differentiation. Prolific Machines'' technology replaces or dramatically reduces the need for these expensive growth factor inputs by using light signals to activate engineered receptors within cells — achieving the same biological responses at a fraction of the cost.

Business Model & Competitive Advantage

The company raised over $55M in total funding, including a $36M Series B in 2023 led by Breakthrough Energy Ventures with co-investment from Prelude Ventures, Ajax Strategies, and Grantham Foundation. While Prolific Machines'' initial application focus is cultivated meat — where growth factor costs represent the dominant barrier to price-competitive cell-grown meat products — its light-activation platform is cell-agnostic and applicable across any biomanufacturing application requiring controlled cell growth: cell therapies, regenerative medicine, biologics manufacturing, and research reagents.

Competitive Landscape 2025–2026

Prolific Machines positions itself as a horizontal biomanufacturing infrastructure company whose core technology can unlock cost reductions across multiple sectors simultaneously. The cultivated meat market serves as an initial high-profile application and proof of concept, but the company''s intellectual property and platform are designed to address the broader $400B+ biomanufacturing market. Its optogenetics-based approach to cell culture control is a genuinely differentiated scientific platform — backed by peer-reviewed research — that addresses a fundamental cost bottleneck in mammalian cell manufacturing.

Founded
2020
Headquarters
Prolific Machines is a Berkeley, California
Curated content • Fact-checked and verified

Key Differentiators

Emerging Innovator

Prolific Machines is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.

Frequently Asked Questions

Similar Brands

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

Regeneron logo

Regeneron

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingFortune500

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

For Prolific Machines

Claim This Profile

Are you from Prolific Machines? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Prolific Machines Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Prolific Machines vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →